Single and multiple dose pharmacokinetics of rifapentine in man: Part II

International Journal of Tuberculosis and Lung Disease

Volumn 3, Issue 5, 1999, Pages 437-444

  Keung, Anther ^a   Eller, M G ^b   McKenzie, K A ^b   Weir, S J ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b North America Pharmacokinetics   (United States)

Author keywords

Metabolism; Pharmacokinetics; Rifapentine

Indexed keywords

25 DEACETYLRIFAPENTINE; ENZYME; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; URINE COLOR; XEROSTOMIA;

ADULT; ANTITUBERCULAR AGENTS; CROSS-OVER STUDIES; HUMANS; MALE; RIFAMPIN;

EID: 0032978862     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Anon. Estimates of future global tuberculosis morbidity and mortality. MMWR 1993; 42: 961-964.
2. Parenti F. New experimental drugs for the treatment of tuberculosis. Rev Infect Dis 1989; 11 (Suppl 2): S479-S483.
3. Acocella G, Pagani V, Marchetti M, Baroni G C, Nicolis F B. Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks. Chemotherapy 1971; 16: 356-370.
4. Kenny M T, Strates B. Metabolism and pharmacokinetics of the antibiotic rifampin. Drug Metab Rev 1981; 12: 159-218.
5. Anon. Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1993; 42 (RR-7): 1-8.
6. Yates M D, Collins C H. Comparison of the sensitivity of mycobacteria to the cyclopentyl rifamycin DL473 and rifamycin. J Antimicrob Chemother 1982; 10: 147-150.
7. Dickinson J M, Mitchison D A. In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle 1987; 68: 113-118.
8. Heifets L B, Lindholm-Levy P J, Flory M A. Bactericidal activity in vitro of various rifamycins against M. avium and M. tuberculosis. Am Rev Respir Dis 1990; 141: 626-630.
9. Birmingham A T, Coleman A J, Orme M L E, et al. Antibacterial activity in serum and urine following oral administration in man of DL473 (a cyclopentyl derivative of rifampicin). Br J Clin Pharmacol 1978; 6: 455P-456P.
10. Buniva G, Sassella D, Frigo G M. Pharmacokinetics of rifapentine in man. Proc Int Congr Chemother 1983; 111: 29-33.
11. Keung A, Reith K, Eller M G, McKenzie K A, Cheng L, Weir S J. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics. Part I. Int J Tuberc Lung Dis 1999; 3: 426-436.
12. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978; 3: 108-127.
13. 14C-rifapentine in healthy volunteers. Drug Metab Dispos 1998; 26: 732-738.
14. Acocella G, Nicolis F B, Lamarina A. A study on the kinetics of rifampicin in man. 5th International Congress of Chemotherapy, Vienna; 1967: 87-93.
15. Skinner M H, Hsieh M, Torseth J, et al. Pharmacokinetics of rifabutin. Antimicrob Agents Chemother 1989; 33: 1237-1241.
16. Cocchiara G, Strolin Benedetti M, Vicario G P, et al. Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers. Xenobiotics 1989; 19: 769-780.
17. 14C-rifabutin in animals and man. J Antimicrob Chemother 1990; 26: 813-822.
18. Loos U, Musch E, Jensen J C, Mikrus G, Schwabe H K, Eichelbaum M. Influence of the enzyme induction by rifampicin on its presystemic metabolism. Pharmacol Ther 1987; 33: 201-204.
19. Mor N, Simon B, Mezo N, Heifets L. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob Agents Chemother 1995; 39: 2073-2077.
20. Arioli V, Berti M, Carniti G, Randist E, Rossi E, Scotti R. Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative. J Antibiot (Tokyo) 1981; 34: 1026-1032.
21. Truffot-Pernot C, Grosser J, Bismuth R, Lecouer H. Activity of intermittent rifampicin and cyclopentyl rifamycin (DL473) in experimental murine tuberculosis. Rev Fr Mal Respir 1983; 11: 875-882.